Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Valbiotis SA ( (FR:ALVAL) ) just unveiled an announcement.
Valbiotis announced the launch of its dietary supplement, Valbiotis®PRO Metabolic Health, in France on February 3rd, targeting metabolic diseases such as type 2 diabetes. The product, based on the TOTUM•63 active substance, is supported by clinical trials and scientific publications, and will be marketed through a multi-channel strategy similar to its previous product, Valbiotis®PRO Cholesterol. This launch is part of Valbiotis’ broader commercial roadmap, which includes upcoming products for blood pressure and hepatic steatosis, strengthening its position in the health nutrition industry.
More about Valbiotis SA
Valbiotis is a French scientific research laboratory specializing in dietary supplements aimed at preventing metabolic and cardiovascular diseases. The company focuses on innovative plant-based health nutrition products to address metabolic disorders and cardiovascular risks, and collaborates extensively with academic institutions. Founded in 2014 in La Rochelle, Valbiotis is recognized for its innovation and has received substantial EU financial support.
YTD Price Performance: -3.07%
Average Trading Volume: 2,106
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €21.53M
See more insights into ALVAL stock on TipRanks’ Stock Analysis page.
